---
layout: post
title: "Bioavailability Studies Submitted in NDAs or INDs-General Considerations; Guidance for Industry; Availability"
date: 2026-02-05 18:58:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-08114
original_published: 2022-04-15 00:00:00 +0000
significance: 8.00
---

# Bioavailability Studies Submitted in NDAs or INDs-General Considerations; Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 15, 2022 00:00 UTC
**Document Number:** 2022-08114

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Bioavailability Studies Submitted in NDAs or INDs--General Considerations." This guidance provides recommendations to sponsors planning to include bioavailability (BA) information for drug products in investigational new drug applications (INDs), new drug applications (NDAs), and NDA supplements. This guidance finalizes the draft guidance of the same title issued on February 26, 2019. This guidance also replaces the draft guidance entitled "Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs--General Considerations" issued March 2014.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/15/2022-08114/bioavailability-studies-submitted-in-ndas-or-inds-general-considerations-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-08114

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
